Xeris Biopharma (NASDAQ:XERS) Announces Earnings Results, Beats Estimates By $0.03 EPS

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings results on Thursday. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.03, FiscalAI reports. The firm had revenue of $107.23 million for the quarter, compared to analysts’ expectations of $101.68 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Xeris reported third-quarter revenue of $107.2 million, up 44% year over year, and raised 2026 revenue guidance to $395 million–$405 million. Management also raised its 2030 revenue outlook from $750 million to more than $1 billion.
• Recorlev revenue nearly doubled year over year to $71.5 million, with record referrals and patient starts following the expanded commercial team’s ramp-up. Management expects momentum to continue, supported by broader screening for hypercortisolism, though access still typically requires prior authorization.
• Gvoke prescriptions rose 5% year over year, but net revenue fell to $21.7 million from $25.2 million a year earlier because of a one-time $4 million Medicaid gross-to-net adjustment. Management said demand improved through the quarter and expects the brand to return to growth.
• KEVEYIS generated $13 million in revenue, its fourth consecutive quarter of year-over-year growth, and received a U.S. patent extending protection through at least 2043. The company plans additional investment to find and support more patients.
• Xeris remains on track to start the pivotal Phase III Cornerstone study of XP-8121 by year-end, with topline results expected in late 2028 and a potential 2030 launch. Management cited peak sales potential of $1 billion–$3 billion, although the opportunity depends on successful clinical development.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $13.08 on Friday. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $2.38 billion, a P/E ratio of -118.91 and a beta of 0.61. Xeris Biopharma has a 12-month low of $5.25 and a 12-month high of $13.74. The firm has a 50-day moving average price of $9.49 and a two-hundred day moving average price of $7.58.

Insiders Place Their Bets

In other news, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the completion of the sale, the insider directly owned 1,614,208 shares in the company, valued at approximately $16,142,080. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total value of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. This trade represents a 0.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 148,332 shares of company stock worth $1,409,221 in the last quarter. Corporate insiders own 4.35% of the company’s stock.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results topped estimates: Xeris reported earnings of $0.06 per share versus the approximately $0.03 consensus, and revenue of $107.23 million versus estimates of $101.68 million. Earnings also improved from break-even a year earlier. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Long-term commercial potential: CEO John Shannon said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected. Xeris also updated its FY2030 earnings guidance; the provided report does not specify the revised figures. Xeris CEO sees Recorlev nearing $1B in annual sales
• Negative Sentiment: Insider selling: Three insiders sold a combined 45,000 shares at $10.23 each. The sales were conducted under pre-arranged Rule 10b5-1 plans, and the sellers retained substantial holdings, which may temper the signal. Xeris Biopharma insider share sale

Wall Street Analysts Forecast Growth

XERS has been the subject of a number of research analyst reports. Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. HC Wainwright boosted their price target on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a research note on Friday. Leerink Partners upped their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Barclays lifted their target price on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, October 6th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.80.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.